Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade A 178.38 -0.89% -1.60
SHPG closed down 0.89 percent on Friday, September 21, 2018, on 80 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical SHPG trend table...

Date Alert Name Type % Chg
Sep 21 Slingshot Bullish Bullish Swing Setup 0.00%
Sep 21 Calm After Storm Range Contraction 0.00%
Sep 21 Overbought Stochastic Strength 0.00%
Sep 20 Stochastic Sell Signal Bearish -0.89%
Sep 20 New 52 Week Closing High Bullish -0.89%
Sep 20 Calm After Storm Range Contraction -0.89%
Sep 20 New 52 Week High Strength -0.89%
Sep 20 Upper Bollinger Band Walk Strength -0.89%
Sep 20 Multiple of Ten Bearish Other -0.89%
Sep 20 Overbought Stochastic Strength -0.89%

Older signals for SHPG ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 181.41
52 Week Low 122.9082
Average Volume 724,674
200-Day Moving Average 156.217
50-Day Moving Average 172.7446
20-Day Moving Average 174.2295
10-Day Moving Average 175.213
Average True Range 2.4026
ADX 23.41
+DI 39.4685
-DI 18.9664
Chandelier Exit (Long, 3 ATRs ) 174.2022
Chandelier Exit (Short, 3 ATRs ) 172.8178
Upper Bollinger Band 181.8852
Lower Bollinger Band 166.5738
Percent B (%b) 0.77
BandWidth 8.788064
MACD Line 1.7506
MACD Signal Line 0.9561
MACD Histogram 0.7945
Fundamentals Value
Market Cap 53.14 Billion
Num Shares 298 Million
EPS 2.23
Price-to-Earnings (P/E) Ratio 79.99
Price-to-Sales 2.82
Price-to-Book 1.34
PEG Ratio 0.84
Dividend 0.92
Dividend Yield 0.52%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 180.85
Resistance 3 (R3) 181.05 180.42 180.44
Resistance 2 (R2) 180.42 179.79 180.32 180.30
Resistance 1 (R1) 179.40 179.40 179.09 179.20 180.16
Pivot Point 178.78 178.78 178.62 178.68 178.78
Support 1 (S1) 177.76 178.15 177.44 177.56 176.60
Support 2 (S2) 177.13 177.76 177.03 176.46
Support 3 (S3) 176.11 177.13 176.32
Support 4 (S4) 175.91